"This is a breakthrough development in the pharmaceutical industry. This technology is based on the use of inorganic acids as active compounds to treat cancer and other diseases of immunological origin," indicated Dr. Manzur Hassanhi, MD, PhD, Senior Medical Research Advisor of Cytorex. "This opens the door for the development of treatments for other diseases," continued Dr. Hassanhi.
"We have so far used a battery of in-vitro screening to test the chemosensitivity of Cytoreg(TM) in human cancers. Results are promising with respect to tumor response. Preliminary data suggest that Cytoreg(TM) has significant inhibitory and anti-proliferating effect on Human breast, testicular, prostate and lung cancers, which were all the cell lines tested at the time," indicated Dr. James Kumi-Diaka, DVM, PhD, Professor of Biology at Florida Atlantic University. "In terms of mechanism of action Cytoreg(TM) induces a selective and dose-dependent Apoptosis (programmed cell death) in the target cells. These preliminary findings are of both diagnostic and therapeutic significance. However, these results need to be translated into in-vivo animal studies - to involve a large animal population, in order to obtain statistically significant results," concluded Dr. Kumi-Diaka.
"We treated five animals with B-16 melanoma, using 1:100 dilution treatments daily. Tumors in four of the animals did not grow, and then one that did appeared to reach a state of no growth. There was no metastasis. A dose response assay is required in a large group of animals. Preliminary data suggest that Cytoreg(TM) definitely is effective against B-16," indicated Dr. Joseph Bryant, Director of the Animal Model Studies Division of the Institute of Biotechnology at the University of Maryland in Baltimore. Bryant performed a limited animal study in B-16 melanoma cells in C57-BL mice.
Additional research with very promising findings was conducted performing several in-vitro and in-vivo assays between the years 2000 and 2002 with grants from Cytorex to Rumbaugh-Goodwin Institute for Cancer Research, Inc., a non-for-profit research facility located in Plantation, Florida.
Cytorex(TM) was developed by Venezuelan Chemist Prof. David Martucci, CEO and Chief Scientific Officer of Cytorex. Martucci has spent over 25 years in research related to the use of inorganic acids for several applications including "pharmacologically active buffered acid solutions," with patent pending status in the United States and Internationally. "This is an invention for humanity," said Martucci. "After we complete all the required testing by FDA in the United States and Drug Approval regulators in other countries, we expect to market our compounds at very reasonable prices in order to make them available to people who cannot afford the cost of cancer treatments available today," concluded Martucci.
About Cytorex Biosciences, Inc.
Cytorex Biosciences, Inc. is an innovative, South Florida based biotechnology company focused on developing compounds to treat cancer and immunological based diseases. Cytorex has world wide intellectual property rights to patent pending Cytoreg(TM) and CytoregUNO(TM). Cytorex is currently in the middle of a private placement offering. This press release is not intended as solicitation. For more information on Cytorex Biosciences, Inc., visit the company's web site at http://www.cytorex.com or call 954-993-4941, Contact Person: Carlos M. Garcia, COO.